Journal of Clinical Oncology最新文献

{"title":"Neoadjuvant Single-Cycle Pembrolizumab for Stage I-III MMR-Deficient Colon Cancer: The RESET-C Trial.","authors":"Ismail Gögenur, Tobias F Justesen, Line S Tarpgaard, Mustafa Bulut, Torben F Hansen, Lars H Jensen, Hans B Rahr, Mikail Gögenur, Tove Kirkegaard, Lukas Balsevicius, Michael Chieng, Hans Raskov, Mia K S Sørensen, Peter C Petersen, Jens R Eriksen, Søren Salomon, Anne-Marie K Fiehn, Maria Dalgaard Mikkelsen, Søren Brandsborg, Kåre A Gotschalck, Katrine J Emmertsen, Anne Ramlov, Pernille W Born, Ole Thorlacius-Ussing, Michael B Lauritzen, René K Olesen, Laurids Ø Poulsen, Jakob Lykke, Jakob Schou, Laura Buskov, Peter-Martin Krarup, Claus L Andersen, Niels Pallisgaard, Per Pfeiffer, Camilla Qvortrup","doi":"10.1200/JCO-25-02274","DOIUrl":"https://doi.org/10.1200/JCO-25-02274","url":null,"abstract":"<p><strong>Purpose: </strong>Neoadjuvant immune checkpoint inhibition has shown promise in localized deficient mismatch repair (dMMR) colorectal cancer, yet the optimal treatment duration, regimen, and methods for response evaluation remain undefined. This trial aimed to investigate the efficacy and safety of neoadjuvant pembrolizumab for patients with localized dMMR colon cancer.</p><p><strong>Methods: </strong>Participants received a single cycle of pembrolizumab (4 mg/kg, max 400 mg, every-6-weeks dosing regimen), followed by a preoperative endoscopy with biopsies and surgery 3-5 weeks later. The primary end point was pathologic complete response (pCR); secondary and exploratory end points included major pathologic response (MPR), safety, survival, and endoscopic response assessment.</p><p><strong>Results: </strong>From February 2023 to March 2024, 85 patients (median age 74 years) were enrolled. All received pembrolizumab; one patient declined surgery. Among 84 patients, pCR was achieved in 44% (37 of 84; 95% CI, 33 to 55), and MPR in 57% (48 of 84; 95% CI, 46 to 68). Two (2%) patients died of complications within 30 days of surgery. At a median follow-up of 18.4 months (IQR, 16.3-21.1), one patient had a recurrence, resulting in overall and disease-free survival rates of 98% and 96%. Grade 3 adverse events occurred in 11% of patients (9 of 85; 95% CI, 3 to 16), with three treatment-related events. In 81 patients, the sensitivity, specificity, and accuracy of the biopsies for predicting pCR were 68%, 75%, and 72%, respectively. In 76 patients, the sensitivity, specificity, and accuracy of the endoscopic images for predicting pCR were 77%, 93%, and 86%, respectively.</p><p><strong>Conclusion: </strong>A single cycle of neoadjuvant pembrolizumab led to pCR in nearly half of patients undergoing surgery for localized dMMR colon cancer. The utility of endoscopic evaluation may inform future strategies for patient selection in nonoperative management pathways.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2502274"},"PeriodicalIF":41.9,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147838490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metastatic Trajectories in Non-Small Cell Lung Cancer Guide Local and Systemic Therapies.","authors":"Jonas Willmann, Edward Christopher Dee, Lizza E L Hendriks, Nikolaos M Dimitriou, Mandy Jongbloed, Adam J Schoenfeld, Alexander Drilon, Karuna Ganesh, Y Helen Zhang, Jill Feldman, Raphael Werner, Isabelle Opitz, Jian Carrot-Zhang, Nikolaus Schultz, Harini Veeraraghavan, David R Jones, Mark Awad, Charles M Rudin, Sanjay Popat, Dirk De Ruysscher, Daniel R Gomez, Matthias Guckenberger, Puneeth Iyengar","doi":"10.1200/JCO-25-01958","DOIUrl":"https://doi.org/10.1200/JCO-25-01958","url":null,"abstract":"<p><p>Advances in systemic therapy have improved outcomes for metastatic non-small cell lung cancer (NSCLC), yet resistance and progression remain nearly universal. Local therapies such as radiotherapy, surgery, and image-guided ablation can extend disease control in selected patients, but existing classifications-including dynamic models of oligometastatic disease-assign a single state per patient and do not capture lesion-level heterogeneity. We introduce the concept of <i>metastatic trajectories</i>-the spatiotemporal dynamics of response and progression across lesions, organs, and patients-as a framework to characterize intrapatient heterogeneity and inform adaptive treatment strategies. Dimensions of metastatic trajectories include the magnitude and homogeneity of response, mechanisms of resistance, organotropism, and the pattern, site, extent, and pace of progression. This framework shifts the focus from overall disease states to individual lesion behavior over time, enabling <i>reactive</i> strategies based on observed trajectories and <i>anticipatory</i> strategies based on predicted ones. We review the biological foundations of intrapatient heterogeneity-including genomic diversification, nongenetic plasticity, and tumor-microenvironmental adaptation-that drive divergent lesion evolution and treatment response. Emerging biomarkers such as circulating tumor DNA and radiomic signatures, together with integrative genomic and functional imaging approaches, may allow tracking and prediction of trajectory evolution. Standardized reporting parameters are proposed to ensure consistent documentation and facilitate validation across studies. Integrating trajectory-based assessment into clinical practice could refine patient selection for local and systemic therapy, enable biology-informed adaptation of treatment timing and intensity, and provide a foundation for next-generation clinical trials aimed at precision management of metastatic NSCLC.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2501958"},"PeriodicalIF":41.9,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147838499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection.","authors":"Risako Komata, Kenju Ando, Akihiko Shimomura, Chikako Shimizu","doi":"10.1200/JCO-26-00140","DOIUrl":"https://doi.org/10.1200/JCO-26-00140","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2600140"},"PeriodicalIF":41.9,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147838539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to: Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection.","authors":"Haoting Shi, Jiahui Huang, Xiaosong Chen, Kunwei Shen","doi":"10.1200/JCO-26-00605","DOIUrl":"https://doi.org/10.1200/JCO-26-00605","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2600605"},"PeriodicalIF":41.9,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147838504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.","authors":"Andrew J Armstrong, Michael J Morris, Wassim Abida, Rahul R Aggarwal, Emmanuel S Antonarakis, Gerhardt Attard, Himisha Beltran, Alan Bryce, Michael A Carducci, Heather H Cheng, Delphine L Chen, Kim N Chi, Daniel S Childs, William Dahut, Louise Emmett, Karim Fizazi, Andrei Gafita, Daniel J George, Ken Hermann, Michael S Hofman, Thomas Hope, Maha Hussain, W Kevin Kelly, Elizabeth Kessler, Phillip H Kuo, Joshua Lang, Glenn Liu, Catherine H Marshall, Alicia K Morgans, Rana R McKay, David Nanus, Peter Nelson, Channing Paller, Zachery R Reichert, Charles J Ryan, A Oliver Sartor, Heiko Schöder, Lawrence H Schwartz, Nima Sharifi, Walter M Stadler, Mark Stein, Cora N Sternberg, Russell Z Szmulewitz, Scott T Tagawa, Alexandra O Sokolova, Alex W Wyatt, Kosj Yamoah, Evan Y Yu, Susan Halabi, Howard I Scher","doi":"10.1200/JCO-25-02834","DOIUrl":"10.1200/JCO-25-02834","url":null,"abstract":"<p><strong>Purpose: </strong>The continuous development of new imaging approaches, molecular phenotyping, genetic subtypes, prognosis assessments, and effective therapies across a range of disease states has created a need to redefine terminology and best practices for clinical trial conduct in patients with advanced prostate cancer.</p><p><strong>Methods: </strong>We convened an international expert committee of diverse working groups, the Prostate Cancer Working Group 4 (PCWG4), between 2016 and 2025. Our objective was to formulate updated criteria based on emerging evidence and clinical trial data in a biomarker context to provide guidance for clinical trial design, eligibility, and end point assessments for patients with advanced prostate cancer.</p><p><strong>Results: </strong>PCWG4 redefines terminology around the disease state and previous therapies in a patient-centric context and terminology focused on androgen pathway modulation. We consider imaging, with a particular focus on positron emission tomography (PET)-defined disease. New recommendations are provided for disease state terminology, defining eligibility criteria, response and delay/prevent end points, intervals for reassessments including imaging, and patient-reported outcome determination. We provide recommendations in a biomarker-based context of use for the intended indication, reflective of patient benefit for specific interventions. We emphasize the need for development of validated PET imaging and molecular and phenotypic criteria as well as trial designs to appropriately risk stratify patients, predict and assess benefit, and measure post-treatment outcomes reliably in a trial framework.</p><p><strong>Conclusion: </strong>PCWG4 updates recommendations on patient and tumor characterization, therapy development, and imaging criteria and extends guidance into earlier androgen pathway modulator-naïve/sensitive disease states to reflect an evolving, heterogeneous, and diverse patient population to optimize treatment benefits for all patients.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"1249-1265"},"PeriodicalIF":41.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13132095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147290143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer.","authors":"Bradley J Stish, Gina L Mazza, Jones T Nauseef, Michael Sandon Humeniuk, Thomas J Smith, Cindy Tofthagen, Dayssy Alexandra Diaz Pardo, Christopher Chay, Andrew J Huang, Kushal Naha, Scott T Tagawa, Selina Chow, Kathryn J Ruddy, Maryam B Lustberg, Lucile L Adams-Campbell, Paul J Novotny, Charles L Loprinzi","doi":"10.1200/JCO-25-01486","DOIUrl":"10.1200/JCO-25-01486","url":null,"abstract":"<p><strong>Purpose: </strong>Hot flashes are a common side effect reported by men receiving androgen-deprivation therapy (ADT) for the treatment of prostate cancer. We sought to determine whether oxybutynin could improve hot flash symptoms in men with prostate cancer.</p><p><strong>Patients and methods: </strong>Patients with prostate cancer receiving a stable regimen of ADT with at least 28 hot flashes per week were randomly assigned to receive either oxybutynin 2.5 mg twice daily, oxybutynin 5 mg twice daily, or matching placebo for 6 weeks. The primary end point was the change in patient-reported hot flash scores since baseline at 6 weeks. Additional outcomes included incidence of adverse events (AEs), changes since baseline in Hot Flash-Related Daily Interference Scale (HFRDIS) scores, and patient-reported symptoms.</p><p><strong>Results: </strong>Eighty-eight patients were enrolled, with the 81 participants eligible for final analysis reporting an average of 10.1 (standard deviation [SD], 5.55) hot flashes per day and an average daily hot flash score of 18.2 (SD, 13.5) included in final analysis. On average, patients on the placebo arm, 2.5 mg oxybutynin arm, and 5 mg oxybutynin arm had reductions in hot flashes/day of 2.15, 4.77 (<i>P</i> = .02), and 6.89 (<i>P</i> < .001), respectively. Daily hot flash scores for placebo, 2.5 mg oxybutynin, and 5 mg oxybutynin reduced by an average of 4.85, 9.94 (<i>P</i> = .07), and 13.95 (<i>P</i> = .002) points, respectively. No treatment-related grade 3+ AEs occurred. HFRDIS total scores improved by 14.2 and 20.7 points in the 2.5 mg (<i>P</i> = .042) and 5 mg (<i>P</i> < .01) oxybutynin arms, respectively, compared with a 3.1-point improvement with placebo.</p><p><strong>Conclusion: </strong>Oxybutynin is superior to a placebo for the management of ADT-associated hot flashes in men with prostate cancer.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"1198-1205"},"PeriodicalIF":41.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12871868/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146052342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.","authors":"Manish R Sharma, John Powderly, Yasutoshi Kuboki, John H Strickler, Ruth Perets, Jonathan E Cohen, Judith Raimboaurg, Takako Eguchi Nakajima, Noboru Yamamoto, Marcia Cruz-Correa, Bert O'Neil, François Ghiringhelli, Kanwal Raghav, Michael Cecchini, Jair Bar, Zoë Hunter, Michael Burns, Martha Blaney, Gladys Morrison-Thiele, Martha Neagu Aristide, Kevin J Freise, Rui Li, Martha Li, Athan Vasilopoulos, Carla Biesdorf, David Sommerhalder","doi":"10.1200/JCO-25-01525","DOIUrl":"https://doi.org/10.1200/JCO-25-01525","url":null,"abstract":"<p><strong>Purpose: </strong>The antibody-drug conjugate Temab-A comprises the c-Met-targeting antibody telisotuzumab conjugated to a novel topoisomerase 1 inhibitor payload, adizutecan. A first-in-human phase I study (ClinicalTrials.gov identifier: NCT05029882) of Temab-A in patients with advanced solid tumors whose disease has progressed is currently ongoing. We report results from all patients in the dose escalation and the monotherapy metastatic colorectal cancer (mCRC) dose expansion.</p><p><strong>Methods: </strong>Temab-A was administered intravenously once every 3 weeks as a monotherapy starting at 1.6 mg/kg in dose escalation. In mCRC dose expansion, patients with confirmed <i>BRAF</i> wild-type, microsatellite stable/mismatch repair-proficient mCRC were randomly assigned to 1.6 mg/kg, 2.4 mg/kg, or 3.0 mg/kg Temab-A once every 3 weeks. Primary end points included safety, pharmacokinetics, recommended phase II dose of Temab-A monotherapy, and Temab-A efficacy in patients with mCRC.</p><p><strong>Results: </strong>In total, 57 patients received ≥1 dose of Temab-A in dose escalation; 3.0 mg/kg once every 3 weeks was established as the maximum tolerated dose. Collectively, in dose escalation and dose expansion, 122 patients with mCRC received Temab-A (dose escalation, N = 29; randomized dose optimization expansion, N = 93). All patients experienced ≥1 treatment-emergent adverse event; the most frequent were gastrointestinal (78%) and hematologic (71%) toxicities. Treatment-related discontinuations and deaths were infrequent (10% and 3%, respectively). Across all doses in patients with mCRC, overall response rate was 15.6% (95% CI, 9.6 to 23.2), disease control rate was 74.6% (95% CI, 65.9 to 82.0), and duration of response was 5.9 months (95% CI, 4.1 to 10.5); responses were more frequent at doses of 2.4 mg/kg and 3.0 mg/kg once every 3 weeks. Median progression-free survival was 4.6 months (95% CI: 4.0, 5.4), and median overall survival was 10.4 months (95% CI, 8.9 to 13.1).</p><p><strong>Conclusion: </strong>Temab-A at 2.4 mg/kg once every 3 weeks has a tolerable and manageable safety profile, with promising antitumor activity.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2501525"},"PeriodicalIF":41.9,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147815779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.","authors":"Corey Cutler, Haesook T Kim, Hassan El Banna, Elizabeth Halloran, Emily Matozel, Vincent T Ho, John Koreth, Mahasweta Gooptu, Roman Shapiro, Amar Kelkar, Christopher Gibson, Sarah Nikiforow, Prashant Nageshwar, Carol Reynolds, Michela Ansuinelli, Rakuyo Tamada, Chloe Au, Kevin Panaro, Casey Gervais, Zachariah DeFilipp, Areej El-Jawahri, Yi-Bin Chen, Najla El Jurdi, Daniel Weisdorf, Daniel Couriel, Catherine Lee, Sally Arai, Bita Sahaf, Juliana Bacigalupi, Kathleen Ji, Robert Soiffer, David Miklos, Joseph H Antin, Jerome Ritz","doi":"10.1200/JCO-25-03104","DOIUrl":"https://doi.org/10.1200/JCO-25-03104","url":null,"abstract":"<p><strong>Purpose: </strong>Chronic graft-versus-host disease (cGVHD) is a multisystem alloimmune disorder associated with abnormal B-cell biology and aberrant antibody responses. As B-cell-directed therapy can effectively treat established cGVHD, we tested whether prophylactic B-cell depletion could prevent the development of corticosteroid-requiring cGVHD following allogeneic transplantation.</p><p><strong>Methods: </strong>We performed a randomized, placebo-controlled, and blinded trial comparing four doses of the B-cell-depleting antibody obinutuzumab (1,000 mg once on days 90, 180, 270, and 365 after transplantation) with placebo in transplant recipients receiving tacrolimus-based GVHD prevention at higher risk of cGVHD. The primary end point was the 1-year incidence of corticosteroid-requiring cGVHD. We measured antibody responses against Y chromosome-encoded minor histocompatibility (H-Y) antigens and correlated their occurrence with corticosteroid-requiring cGVHD incidence.</p><p><strong>Results: </strong>One hundred seventy-eight participants were analyzed. The prophylactic administration of obinutuzumab resulted in profound B-cell depletion, a significant reduction in the incidence of steroid-requiring cGVHD at 1 year (13.3% <i>v</i> 35.2%; <i>P</i> = .0005), and an improvement in immunosuppression-free, relapse-free survival (48% <i>v</i> 34% at 2 years; <i>P</i> = .02). Neutropenia was more common in the obinutuzumab arm, but nonrelapse mortality was not different. In participants without preformed H-Y antibodies at the time of study intervention, obinutuzumab resulted in the most significant reduction in steroid-requiring cGVHD at 12 months (8.6%) compared with obinutuzumab participants with H-Y antibodies (40%) or placebo participants regardless of antibody status (41% with antibodies, 57% without antibodies).</p><p><strong>Conclusion: </strong>In allogeneic transplant recipients at higher risk of cGVHD, early B-cell depletion results in a significant reduction in the incidence of corticosteroid-requiring cGVHD.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2503104"},"PeriodicalIF":41.9,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147815773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: First-In-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01.","authors":"Toshio Shimizu, Jacob Sands, Kiyotaka Yoh, Alexander Spira, Edward B Garon, Satoru Kitazono, Melissa L Johnson, Funda Meric-Bernstam, Anthony W Tolcher, Noboru Yamamoto, Jon Greenberg, Yui Kawasaki, Hong Zebger-Gong, Fumiaki Kobayashi, Penny Phillips, Aaron E Lisberg, Rebecca S Heist","doi":"10.1200/JCO-26-00937","DOIUrl":"https://doi.org/10.1200/JCO-26-00937","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2600937"},"PeriodicalIF":41.9,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147815726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Watch and Wait for Rectal Cancer: A Risky Gamble or a Safe Strategy for Patients With a Near-Complete Response?","authors":"Fahima Dossa, Trevor Yeung, Julio Garcia-Aguilar","doi":"10.1200/JCO-25-01752","DOIUrl":"https://doi.org/10.1200/JCO-25-01752","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2501752"},"PeriodicalIF":41.9,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147771949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}